Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 5858-year-old woman is brought to the emergency department by her husband due to progressive confusion, lethargy, and a witnessed generalized tonic-clonic seizure at home. She has a history of small cell lung cancer and is currently undergoing chemotherapy. Her temperature is 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure is 134/82 mmHg134/82 \text{ mmHg}, pulse is 88/min88/\text{min}, and respiratory rate is 16/min16/\text{min}. She is somnolent but arousable to painful stimuli. Laboratory testing reveals a serum sodium concentration of 110 mEq/L110 \text{ mEq/L}, serum osmolality of 240 mOsm/kg240 \text{ mOsm/kg}, and urine osmolality of 650 mOsm/kg650 \text{ mOsm/kg}. A diagnosis of syndrome of inappropriate antidiuretic hormone secretion (SIADH) causing severe, symptomatic hyponatremia is made.

Arrange the following monitoring and therapeutic evaluation steps in the most appropriate chronological sequence for managing this patient's acute presentation.

  1. 1Infuse an initial 100 mL100 \text{ mL} bolus of 3%3\% hypertonic saline over 1010 minutes.
  2. 2Reassess neurologic symptoms and measure serum sodium to evaluate the effect of the initial therapy.
  3. 3Administer subsequent 100 mL100 \text{ mL} boluses of 3%3\% hypertonic saline if life-threatening manifestations persist.
  4. 4Terminate hypertonic saline administration upon cessation of severe symptoms or a 5 mEq/L5 \text{ mEq/L} rise in serum sodium.
  5. 5Initiate strict fluid restriction and monitor serum sodium periodically to prevent a 2424-hour correction exceeding 8 mEq/L8 \text{ mEq/L}.

Cevap

The correct sequence is to first infuse an initial bolus of 3%3\% hypertonic saline, followed by reassessing symptoms and serum sodium. If symptoms persist, subsequent boluses are administered. Once symptoms resolve or sodium rises by 5 mEq/L5 \text{ mEq/L}, the infusion is terminated. Finally, fluid restriction is initiated with periodic monitoring to ensure the 2424-hour correction limit is not exceeded.
The appropriate protocol for severe symptomatic hyponatremia begins with immediate administration of a 3%3\% hypertonic saline bolus to reverse cerebral edema. This is followed by immediate reassessment. If symptoms persist, further boluses are indicated. The aggressive phase of treatment stops as soon as severe symptoms resolve or the sodium rises by 5 mEq/L5 \text{ mEq/L}. The final phase is maintenance therapy (e.g., fluid restriction for SIADH) and ongoing monitoring to ensure the total correction does not exceed 8 mEq/L8 \text{ mEq/L} in the first 2424 hours.

Adım Adım Çözüm

1
Administer initial 3%3\% hypertonic saline bolus.
Rapid mobilization of water out of brain cells, decreasing cerebral edema.
The patient is actively seizing or post-ictal with profound hyponatremia (110 mEq/L110 \text{ mEq/L}), requiring immediate life-saving intervention.
2
Check serum sodium and reassess neurologic status.
Determination of whether the initial dose successfully reversed the severe cerebral edema.
Monitoring the response is required before deciding whether to continue aggressive therapy or transition to maintenance.
3
Administer additional boluses if required.
Further correction of hyponatremia if the initial response was inadequate.
Persistent severe symptoms indicate ongoing significant cerebral edema that requires continued rapid correction.
4
Discontinue hypertonic saline.
Cessation of rapid serum sodium elevation.
A 5 mEq/L5 \text{ mEq/L} increase is typically sufficient to reverse severe cerebral edema; continuing hypertonic therapy risks osmotic demyelination syndrome.
5
Transition to fluid restriction and ongoing monitoring.
Gradual correction of the remaining hyponatremia while addressing the underlying SIADH.
To safely manage the patient over the next 2424 to 4848 hours, avoiding a correction rate greater than 8 mEq/L8 \text{ mEq/L} per day.

Anahtar Kavram

The acute management of severe symptomatic hyponatremia involves immediate boluses of 3%3\% hypertonic saline, close monitoring of clinical response, and strict cessation of hypertonic therapy once acute symptoms resolve to prevent osmotic demyelination.
Tahmini Süre:1m 30s
Bu soruyu puanla